| abstract |
REFERS TO A COMPOUND OF FORMULA (I) WHERE: ---- IT IS A CARBON-CARBON SINGLE LINK AND A CARBON-CARBON DOUBLE LINK; R1 IS H, METHYL, AND N PROTECTIVE GROUP; R2 IS H, HALO, HYDROXY, METHYL, CYCLOPROPYL AND CYCLOBUTYL; R3 IS H, HALO, OXO, AND METHYL; R4 IS HALO, NITRO, CYANE, AZIDO, AMONG OTHERS; R5 IS H, HYDROXY, ALKYL, ALKENYL, AMONG OTHERS; L IS A LINK, OC (H) 2, C (H) 2O, C1-C2 ALKYLENE, CYCLOPROPYL-1,2-ENO; R6 IS 2-RING FUSED CARBOYCLYL AND 2-RING FUSED HETERO CYCLYL. A PREFERRED COMPOUND IS N- (6- (5- (2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H) -IL) -3-IODO-2-METHOXYPHENYL) NAPHTHALEN-2-IL) METANSULFONAMIDE, BETWEEN OTHERS. SAID COMPOUND HAS AN X-RAY DIFFRACTION PATTERN OF POWDERS EXPRESSED IN DEGREES 2 TETHA OF: 8.3 ± 0.2, 9.7 ± 0.2, 10.6 ± 0.2, 13.6 ± 0.2 , 17.2 ± 0.2, 19.2 ± 0.2, 22, 22.7 ± 0.2, AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SAID COMPOUND IS INHIBITOR OF THE VIRUS OF HEPATITIS C |